Search Virginia Mason News

SEATTLE – (June 4, 2014) — Kris Kowdley, MD, director of the Liver Center of Excellence at Virginia Mason, is the lead author of the recent article in the New England Journal of Medicine about a study in which a pill containing ledipasvir and sofosbuvir cured more than 90 percent of non-cirrhotic hepatitis C (HCV) patients.

In all, 647 patients participated in drug trials at Virginia Mason and other research centers around the nation as part of the study. Researchers determined that 94 percent of patients with chronic HCV genotype 1 and no cirrhosis were able to treat the virus after just eight weeks with a single, once-daily pill containing the medications sofosbuvir (Sovaldi) and ledipasvir.

The study also concluded that adding ribavirin or extending treatment to 12 weeks did not significantly improve the results. The eight-week regimen of ledipasvir–sofosbuvir has not yet been evaluated in patients with cirrhosis.

The study and the medication have received broad media coverage: 

About Virginia Mason
Virginia Mason, founded in 1920, is a nonprofit regional health care system in Seattle that serves the Pacific Northwest. Virginia Mason employs more than 5,600 people and includes a 336-bed acute-care hospital; a primary and specialty care group practice of more than 460 physicians; satellite locations throughout the Puget Sound area; and Bailey-Boushay House, the first skilled-nursing and outpatient chronic care management program in the U.S. designed and built specifically to meet the needs of people with HIV/AIDS. Benaroya Research Institute at Virginia Mason is internationally recognized for its breakthrough autoimmune disease research. Virginia Mason was the first health system to apply lean manufacturing principles to health care delivery to eliminate waste, lower cost, and improve quality and patient safety.

To learn more about Virginia Mason, please visit or follow @VirginiaMason on Twitter. To learn how Virginia Mason is transforming health care and to join the conversation, visit our blog at

Media Contact:
Gale Robinette
Virginia Mason Media Relations
(206) 341-1509

Back to Search